Validation Study of Ventana SP263 PD-L1 Immunohistochemistry Antibody Assay as LDT for Clinical Use in patients with NSCLC being considered for Keytruda Therapy

被引：0
|
作者：
Marolt, Monna [1 ]
Racila, Emilian [2 ]
机构：
[1] Fairview Hlth Serv, Wyoming, MN USA
[2] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA
来源：
LABORATORY INVESTIGATION | 2019年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1857
引用
收藏
页数：2
相关论文
共 50 条
  • [11] PD-L1 (SP263) staining of fine needle aspirate FFPE samples in NSCLC
    Hayden, D.
    Roland, B.
    Saufkie, K.
    Largo, S.
    Ahmadi, P.
    Vasquez, M.
    Newell, A. E. Hanlon
    Schnittker, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1113 - S1113
  • [12] An interobserver reproducibility study on PD-L1 (SP263) in urothelial carcinoma
    Barut, N. B.
    Hurdogan, O.
    Kilicaslan, I.
    Ozluk, Y.
    VIRCHOWS ARCHIV, 2024, 485 : S521 - S521
  • [13] Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors.
    Oyan, Basak
    Sonmez, Ozlem
    Yazar, Aziz
    Teomet, Mehmet
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [14] PD-L1 status by SP142 and sp263 immunohistochemistry in triple-negative breast cancer
    Cordoba, A.
    Mercado, M. D. R.
    Amat, I.
    Beloqui, R.
    Aguiar, B.
    Rodriguez, Y.
    Guerrero-Setas, D.
    VIRCHOWS ARCHIV, 2020, 477 : S44 - S44
  • [15] A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade
    Cortellini, Alessio
    Zampacorta, Claudia
    De Tursi, Michele
    Grillo, Lucia R.
    Ricciardi, Serena
    Bria, Emilio
    Martini, Maurizio
    Giusti, Raffaele
    Filetti, Marco
    Dal Mas, Antonella
    Russano, Marco
    Dall'Olio, Filippo Gustavo
    Buttitta, Fiamma
    Marchetti, Antonio
    PATHOLOGICA, 2024, 116 (04) : 222 - 231
  • [16] Interobserver agreement of PD-L1 (SP263) assessment in advanced NSCLC on cytological smears and histological samples
    Ambrosi, Francesca
    Giunchi, Francesca
    Capizzi, Elisa
    Cancellieri, Alessandra
    Trisolini, Rocco
    Ardizzoni, Andrea
    Fiorentino, Michelangelo
    Ricci, Costantino
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 233
  • [17] Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients
    Li, Wenbin
    Song, Peng
    Guo, Lei
    Liu, Xiuyun
    Guo, Changyuan
    Ying, Jianming
    Gao, Shugeng
    THORACIC CANCER, 2019, 10 (02) : 175 - 182
  • [18] Investigation of PD-L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with VENTANA PD-L1 (SP263) assay and Combined Positive Score (CPS)
    Chao, Y.
    Yang, S.
    Zhang, Y.
    Shen, Z.
    Wu, X.
    Wang, J.
    Quiroz, M.
    Nielsen, A.
    Liu, C.
    Desai, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S300 - S300
  • [19] PD-L1 expression in muscle invasive urothelial carcinoma: Comparison of SP142 and SP263 assay
    Gupta, Gurudutt
    Pasricha, Sunil
    Kamboj, Meenakshi
    Sharma, Anila
    Nayana, N. S.
    Durga, Garima
    Sharma, Anurag
    Rawal, Sudhir
    Meh, Anurag
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2022, 65 (04) : 839 - 843
  • [20] Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors
    Marchetti, Antonio
    Barberis, Massimo
    Franco, Renato
    De Luca, Graziano
    Pace, Maria Vittoria
    Staibano, Stefania
    Volante, Marco
    Buttitta, Fiamma
    Guerini-Rocco, Elena
    Righi, Luisella
    D'antuono, Tommaso
    Scagliotti, Giorgio V.
    Pinto, Carmine
    De Rosa, Gaetano
    Papotti, Mauro
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : 1654 - 1663
12345